Sixteen patients were alive at time of analysis. Median follow-up was 4.1 years for all patients and 14 years for living patients. At 15 years, local control rate was 78%, regional control rate was 92%, and localregional control rate was 74%. Cause-specific and disease-free survival rates were 49% at 5 years and 35% at 10 and 15 years. Fifteen percent had a contralateral breast failure. The rate of distant metastases was 59% at 10 years and 61% at 15 years. Overall survival rate was 48% at 5 years, 32% at 10 years, and 23% at 15 years. The 10 patients who received preoperative RT (median dose, 55 Gy) but not surgery fared poorly, with 9 dying of disease; the median time to death was 1.4 years. The 10-year survival rate for the no-surgery group was 20% compared to 25% in the preoperative RT and surgery group and 35% in the postoperative RT group (P Z 0.22). Patients treated once daily (median dose, 50 Gy) had a 10-year local control rate of 78% and regional control rate of 91%. This was comparable to the twice-daily arm (median dose, 51 Gy), which had a local control rate of 76% (P Z 0.69) and regional control rate of 100% (P Z 0.22). Per CTCAE version 4.0, 26 (30.2%) patients experienced lymphedema: 3 with grade 3; 11 with grade 2; 12 with grade 1. In 5 of these patients, lymphedema was permanent. There were 6 grade 3 and 1 grade 4 complications during chemotherapy. No grade 5 toxicity occurred. Conclusion: IBC is an aggressive disease that is routinely self-detected by patients. Once-daily versus twice-daily RT did not affect control rates in this cohort. Patients who did not receive trimodality therapy, especially those who did not proceed to surgery, had a particularly poor prognosis. Nearly a quarter of patients achieve long-term survival.
Conclusion: Our work suggests that LD should not be an absolute contraindication to checkpoint blockade administration, and a clinical benefit persists for the immune-stimulatory effects of both aPD-1/L1 and RT even in the presence of supra-physiologic doses of glucocorticoids. More study is needed for HD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.